MedTrace Logo

A Study of Imaging in Demyelinating Diseases

NCT05805839 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-08-29

No results posted yet for this study

Summary

This purpose of this study is research the usefulness of MRI with PET/CT imaging for measuring brain inflammation and its relation to Multiple Sclerosis (MS).

Conditions

Interventions

DRUG

C-11 ER176 Radiotracer

Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).

DRUG

C11 Pittsburgh Compound B

Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).

DIAGNOSTIC_TEST

PET/CT scan

Imaging of entire brain

DIAGNOSTIC_TEST

MRI

Magnetic Resonance Imaging of the Brain

Sponsors & Collaborators

Principal Investigators

  • Burcu Zeydan, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2028-05-31
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05805839 on ClinicalTrials.gov